Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Technology appraisal guidance
Reference number: TA509
Published:
Following the submission of further analyses by the company, including an updated commercial access arrangement, the committee will meet again to discuss the appraisal of pertuzumab for metastatic breast cancer on 9 May 2017.